A5047034614- Diabetes Management and Research
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Diabetes Treatment and Management
- Diabetes Management and Education
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Chronic Disease Management Strategies
- Statistical Methods in Clinical Trials
- Family and Disability Support Research
- Optimal Experimental Design Methods
- Biosimilars and Bioanalytical Methods
- Mobile Health and mHealth Applications
- Pharmaceutical studies and practices
- Cardiac pacing and defibrillation studies
- Gestational Diabetes Research and Management
- Corneal Surgery and Treatments
- Spectroscopy Techniques in Biomedical and Chemical Research
- Sympathectomy and Hyperhidrosis Treatments
- Urban Transport and Accessibility
- Vehicle emissions and performance
- Blood Pressure and Hypertension Studies
- Infant Development and Preterm Care
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Gene expression and cancer classification
- Optical Imaging and Spectroscopy Techniques
Jaeb Center for Health Research
2018-2025
University of North Carolina at Chapel Hill
2023
University of Tampa
2020-2021
University of Colorado Anschutz Medical Campus
2020
National Transportation Safety Board
2020
National Institute of Diabetes and Digestive and Kidney Diseases
2020
Stanford University
2020
University of Minnesota
2020
Yale University
2020
Houston Methodist Sugar Land Hospital
2020
A closed-loop system of insulin delivery (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes.
Adolescents and young adults with type 1 diabetes exhibit the worst glycemic control among individuals across lifespan. Although continuous glucose monitoring (CGM) has been shown to improve in adults, its benefit adolescents not demonstrated.To determine effect of CGM on diabetes.Randomized clinical trial conducted between January 2018 May 2019 at 14 endocrinology practices US including 153 aged 24 years screening hemoglobin A1c (HbA1c) 7.5% 10.9%.Participants were randomized 1:1 undergo...
<h3>Importance</h3> Continuous glucose monitoring (CGM) provides real-time assessment of levels and may be beneficial in reducing hypoglycemia older adults with type 1 diabetes. <h3>Objective</h3> To determine whether CGM is effective compared standard blood (BGM) <h3>Design, Setting, Participants</h3> Randomized clinical trial conducted at 22 endocrinology practices the United States among 203 least 60 years age <h3>Interventions</h3> Participants were randomly assigned a 1:1 ratio to use...
Abstract Context Minority young adults (YA) currently represent the largest growing population with type 1 diabetes (T1D) and experience very poor outcomes. Modifiable drivers of disparities need to be identified, but are not well-studied. Objective To describe racial-ethnic among YA T1D identify glycemic disparity other than socioeconomic status (SES). Design Cross-sectional multicenter collection patient chart-reported variables, including SES, social determinants health, diabetes-specific...
Closed-loop insulin delivery systems have the potential to address suboptimal glucose control in children and adolescents with type 1 diabetes. We compared safety efficacy of Cambridge hybrid closed-loop algorithm usual care over 6 months this population.
Objective: To evaluate glycemic outcomes in the Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) randomized clinical trial (RCT) participants during an observational extension phase. Research Design and Methods: WISDM RCT was a 26-week comparing continuous glucose monitoring (CGM) blood (BGM) 203 adults aged ≥60 years type 1 diabetes. Of 198 who completed RCT, 100 (98%) CGM group continued (CGM-CGM cohort) 94 BGM initiated (BGM-CGM additional 26 weeks. Results: used median of...
To evaluate the association between continuous glucose monitoring (CGM)-based time in various ranges and subsequent development of diabetic retinopathy (incident DR) adults with type 1 diabetes.
Background: In a prior work, virtual continuous glucose monitoring (CGM) trace was generated for each of the 1441 participants in landmark Diabetes Control and Complications trial (DCCT). These new data allow us to compare whether time-in-tight-range (TITR) is better predictor diabetic microvascular complications (specifically retinopathy development or progression) than time-in-range (TIR). Methods: Discrete Cox proportional hazard models were used calculate ratios (HRs)...
Automated insulin delivery (AID) systems have been shown to be beneficial for patients with type 1 diabetes, but data are needed from randomized, controlled trials regarding their role in the management of insulin-treated 2 diabetes. In this 13-week, multicenter trial, adults diabetes were randomly assigned a 2:1 ratio receive AID or continue pretrial insulin-delivery method (control group); both groups received continuous glucose monitoring (CGM). The primary outcome was glycated hemoglobin...
Background: Studies of closed-loop control (CLC) in patients with type 1 diabetes (T1D) consistently demonstrate improvements glycemic as measured by increased time-in-range (TIR) 70-180 mg/dL. However, clinical predictors TIR users CLC systems are needed. Materials and Methods: We analyzed data from 100 children aged 6-13 years T1D using the Tandem Control-IQ system during a randomized trial or subsequent extension phase. Continuous glucose monitor were collected at baseline 12-16 weeks...
Introduction: Hybrid closed-loop systems increase time-in-range (TIR) and reduce glycemic variability. Person-reported outcomes (PROs) are essential to assess the utility of new devices their impact on quality life. This article focuses PROs for pediatric participants (ages 6-13 years) with type 1 diabetes (T1D) parents during a trial using Tandem Control-IQ system, which was shown TIR improve other metrics. Research Design Methods: One hundred one children 6 13 years old T1D were randomly...
To further evaluate the safety and efficacy of Control-IQ closed-loop control (CLC) system in children with type 1 diabetes.After a 16-week randomized clinical trial (RCT) comparing CLC sensor-augmented pump (SAP) therapy 101 6-13 years old diabetes, 22 participants SAP group initiated use (referred to as SAP-CLC cohort), 78 continued (CLC-CLC cohort) for 12 weeks.In cohort, mean percentage time range 70-180 mg/dL (TIR) increased from 55 ± 13% using during RCT 65 10% (P < 0.001), 36% cohort...
Background: Although insulin pump infusion set failures are common, studies assessing the failure rate limited. Methods: Data were analyzed from two clinical trials, in which 263 participants aged 6-72 years used 22,741 sets. The frequency of removal due to prolonged hyperglycemia (continuous glucose monitor measuring >300 mg/dL immediately before and >250 continuously for at least 2 h with 90 min out prior 120 min) was determined. Differences rates among age groups types evaluated. Results:...
Abstract Aim To examine changes in the lived experience of type 1 diabetes after use hybrid closed loop (CL), including CamAPS FX CL system. Materials and Methods The primary study was conducted as an open‐label, single‐period, randomized, parallel design contrasting versus insulin pump (with or without continuous glucose monitoring). Participants were asked to complete patient‐reported outcomes before starting 3 6 months later. Surveys assessed distress, hypoglycaemia concerns quality life....
BackgroundOlder adults with type 1 diabetes are at risk for serious hypoglycemia. Automated insulin delivery can reduce but has not been sufficiently evaluated in this population.MethodsWe conducted a multicenter, randomized crossover trial older than or equal to 65 years of age diabetes. Participants completed three 12-week periods using hybrid closed loop, predictive low-glucose suspend, and sensor-augmented pump order. The primary outcome was the percentage time continuous glucose...
Knowledge regarding the burden and predictors of hypoglycemia among older adults with type 1 diabetes (T1D) is limited.
Abstract Context Continuous glucose monitoring (CGM) is increasingly being used both for day-to-day management in patients with diabetes and clinical research. While data on glycemic profiles of healthy, nondiabetic individuals exist, very young children are lacking. Objective This work aimed to establish reference sensor ranges children, using a current-generation CGM sensor. Methods prospective observational study took place an institutional practice aged 1 6 years normal body mass index....
The Automated Insulin Delivery in Elderly with Type 1 Diabetes (AIDE T1D) trial randomized 82 adults ≥65 years type diabetes (T1D) to hybrid closed loop (HCL), predictive low glucose suspend (PLGS), and sensor-augmented pump (SAP) therapy a crossover trial. Seventy-five of the 78 completers joined an extension phase which they were offered mode their choice for additional 3 months. Mean age was 71 ± 4 (range 65-86 years) mean duration T1D 42 17 1-68 years). Use HCL selected by 91%, PLGS 8%,...
Background: No published data are available on the use of community-derived open-source Loop hybrid closed-loop controller ("Loop") by individuals with type 2 diabetes (T2D).
Background: Older adults with T1D are a growing population at risk for severe hypoglycemia. Automated insulin delivery (AID) approaches that can reduce have not been sufficiently evaluated in this population. Methods: We conducted multicenter, randomized, crossover trial ≥65 years experiencing hypoglycemia (&gt;1.5% time &lt; 70 mg/dL based on CGM). Participants completed 3 sequential 12-week periods of hybrid-closed (HCL) loop Tandem Control-IQ technology, predictive low glucose...
Objective: To evaluate a transition from standard-of-care (SC) management of type 1 diabetes (any insulin delivery method including hybrid closed-loop systems plus real-time continuous glucose monitoring [CGM]) to use the insulin-only configuration iLet® bionic pancreas (BP) in 90 adults and children (age 6-71 years). Research Design Methods: After SC group completed randomized controlled trial (RCT) portion Insulin-Only BP Pivotal Trial, 107 participants participated 13-week study using BP....
Managing type 1 diabetes in young children can cause significant stress for parents. Continuous glucose monitoring (CGM) may reduce parental burden. The Strategies to Enhance CGM Use Early Childhood (SENCE) trial randomized parents of (ages 2 <8 years) with family behavioural intervention (CGM + FBI), alone (Standard-CGM) or blood 26 weeks before receiving FBI (BGM-Crossover). This report assesses changes psychosocial outcomes all groups over 52 weeks.